{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:22:06Z","timestamp":1791015726146,"version":"4.1.0"},"reference-count":161,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Basic Science Research Program of the National Research Foundation of Korea (NRF) by the Ministry of Science, ICT and Future Planning","award":["NRF-2021R1C1C2009289"],"award-info":[{"award-number":["NRF-2021R1C1C2009289"]}]},{"name":"Basic Science Research Program of the National Research Foundation of Korea (NRF) by the Ministry of Science, ICT and Future Planning","award":["2020R1A5A2017323"],"award-info":[{"award-number":["2020R1A5A2017323"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Retinopathy of prematurity (ROP) is a rare proliferative ocular disorder in preterm infants. Because of the advancements in neonatal care, the incidence of ROP has increased gradually. Now, ROP is one of the leading causes of blindness in children. Preterm infants with immature retinal development are exposed to supplemental oxygen inside an incubator until their cardiopulmonary system is adequately developed. Once they are returned to room air, the relatively low oxygen level stimulates various angiogenesis factors initiating retinal neovascularization. If patients with ROP are not offered adequate and timely treatment, they can experience vision loss that may ultimately lead to permanent blindness. Although laser therapy and anti-vascular endothelial growth factor agents are widely used to treat ROP, they have limitations. Thus, it is important to identify novel therapeutics with minimal adverse effects for the treatment of ROP. To date, various pharmacologic and non-pharmacologic therapies have been assessed as treatments for ROP. In this review, the major molecular factors involved in the pathogenesis of ROP, currently offered therapies, therapies under investigation, and emerging novel therapeutics of ROP are discussed.<\/jats:p>","DOI":"10.3390\/ijms23158529","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T21:01:24Z","timestamp":1659387684000},"page":"8529","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["New Aspects on the Treatment of Retinopathy of Prematurity: Currently Available Therapies and Emerging Novel Therapeutics"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-1626","authenticated-orcid":false,"given":"Juhee","family":"Ryu","sequence":"first","affiliation":[{"name":"Vessel-Organ Interaction Research Center, College of Pharmacy, Kyungpook National University, Daegu 41566, Korea"},{"name":"Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu 41566, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev-vision-091517-034018","article-title":"Retinal Vasculature in Development and Diseases","volume":"4","author":"Sun","year":"2018","journal-title":"Annu. Rev. Vis. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1542\/peds.2004-1309","article-title":"Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network","volume":"115","author":"Darlow","year":"2005","journal-title":"Pediatrics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1542\/peds.2004-1413","article-title":"The incidence and course of retinopathy of prematurity: Findings from the early treatment for retinopathy of prematurity study","volume":"116","author":"Good","year":"2005","journal-title":"Pediatrics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40942-018-0125-z","article-title":"Incidence and risk factors for retinopathy of prematurity: A retrospective cohort study","volume":"4","author":"Freitas","year":"2018","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International Classification of Retinopathy of Prematurity, Third Edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","article-title":"Screening Examination of Premature Infants for Retinopathy of Prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.clp.2014.08.011","article-title":"Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity","volume":"41","author":"Hartnett","year":"2014","journal-title":"Clin. Perinatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Dai, C., Webster, K.A., Bhatt, A., Tian, H., Su, G., and Li, W. (2021). Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094809"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1542\/peds.112.5.1016","article-title":"Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth","volume":"112","author":"Carlsson","year":"2003","journal-title":"Pediatrics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1167\/iovs.08-2521","article-title":"Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy","volume":"50","author":"Chen","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.92.3.905","article-title":"Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization","volume":"92","author":"Pierce","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","first-page":"290","article-title":"Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity","volume":"37","author":"Stone","year":"1996","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1056\/NEJMoa041773","article-title":"Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy","volume":"353","author":"Watanabe","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Smith","year":"2013","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","article-title":"Pathophysiology and mechanisms of severe retinopathy of prematurity","volume":"122","author":"Hartnett","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s11481-014-9531-7","article-title":"Vascular endothelial growth factor signaling in hypoxia and inflammation","volume":"9","author":"Ramakrishnan","year":"2014","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in Signaling and Disease: Beyond Discovery and Development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: Basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.yexcr.2005.11.012","article-title":"Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis","volume":"312","author":"Shibuya","year":"2006","journal-title":"Exp. Cell Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/mvre.1998.2111","article-title":"Increased expression of KDR\/Flk-1 (VEGFR-2) in murine model of ischemia-induced retinal neovascularization","volume":"56","author":"Suzuma","year":"1998","journal-title":"Microvasc. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm0603-677","article-title":"Regulation of angiogenesis by hypoxia: Role of the HIF system","volume":"9","author":"Pugh","year":"2003","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"239356","DOI":"10.1155\/2014\/239356","article-title":"The hypoxia-inducible factor pathway, prolyl hydroxylase domain protein inhibitors, and their roles in bone repair and regeneration","volume":"2014","author":"Fan","year":"2014","journal-title":"Biomed Res. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1167\/iovs.11-8002","article-title":"Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration","volume":"52","author":"Huang","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/j.1582-4934.2008.00243.x","article-title":"Deguelin inhibits retinal neovascularization by down-regulation of HIF-1alpha in oxygen-induced retinopathy","volume":"12","author":"Kim","year":"2008","journal-title":"J. Cell. Mol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1167\/iovs.02-0276","article-title":"Potential role of the angiopoietin\/tie2 system in ischemia-induced retinal neovascularization","volume":"44","author":"Takagi","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/01.RES.83.3.233","article-title":"Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization","volume":"83","author":"Asahara","year":"1998","journal-title":"Circ. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/labinvest.3780433","article-title":"Stable expression of angiopoietin-1 and other markers by cultured pericytes: Phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo","volume":"82","author":"Sundberg","year":"2002","journal-title":"Lab. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ajo.2010.08.037","article-title":"Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity","volume":"151","author":"Sato","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"15732","DOI":"10.1074\/jbc.274.22.15732","article-title":"Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells","volume":"274","author":"Oh","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.2337\/dc06-0556","article-title":"Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema","volume":"29","author":"Fonollosa","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood.V93.8.2627","article-title":"Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo","volume":"93","author":"Ribatti","year":"1999","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/emboj\/cdg117","article-title":"HLF\/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin","volume":"22","author":"Morita","year":"2003","journal-title":"EMBO J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaapos.2005.09.005","article-title":"Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity","volume":"10","author":"Brown","year":"2006","journal-title":"J. AAPOS"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000342548","article-title":"IGF-I in human growth: Lessons from defects in the GH-IGF-I axis","volume":"71","author":"Hwa","year":"2013","journal-title":"Nestle Nutr. Inst. Workshop Ser."},{"key":"ref_37","first-page":"IX","article-title":"Recent advances in growth research: Nutritional, molecular and endocrine perspectives. Preface","volume":"71","author":"Gillman","year":"2013","journal-title":"Nestle Nutr. Inst. Workshop Ser."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5958","DOI":"10.1210\/en.2008-0920","article-title":"Expanding the mind: Insulin-like growth factor I and brain development","volume":"149","author":"Ye","year":"2008","journal-title":"Endocrinology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1073\/pnas.101113998","article-title":"Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity","volume":"98","author":"Hellstrom","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/70963","article-title":"Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor","volume":"5","author":"Smith","year":"1999","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000087587","article-title":"IGF-1 and retinopathy of prematurity in the preterm infant","volume":"88","author":"Smith","year":"2005","journal-title":"Biol. Neonate"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12041-009-0068-0","article-title":"Mediators of ocular angiogenesis","volume":"88","author":"Qazi","year":"2009","journal-title":"J. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/1933719107304563","article-title":"Matrix metalloproteinases and their tissue inhibitors in preterm perinatal complications","volume":"14","author":"Cockle","year":"2007","journal-title":"Reprod. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.1167\/iovs.03-0249","article-title":"Reduced Retinal Angiogenesis in MMP-2\u2013Deficient Mice","volume":"44","author":"Uetama","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1001\/archopht.117.4.498","article-title":"Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor","volume":"117","author":"Das","year":"1999","journal-title":"Arch. Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/aos.12266","article-title":"Intravitreal low-dosage bevacizumab for retinopathy of prematurity","volume":"92","author":"Harder","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1111\/aos.13004","article-title":"Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: A case series with paired-eye comparison","volume":"96","author":"Han","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Kennedy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","article-title":"Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors","volume":"124","author":"Huang","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II","volume":"22","author":"Autrata","year":"2012","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5301\/ejo.5000938","article-title":"Effect of Intravitreal Aflibercept on Central Retinal Arterial Blood Flow in Type 1 Retinopathy of Prematurity","volume":"27","author":"Sukgen","year":"2017","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s12094-011-0720-z","article-title":"Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer","volume":"13","author":"Koukourakis","year":"2011","journal-title":"Clin. Transl. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40272-020-00433-z","article-title":"Ranibizumab: A Review in Retinopathy of Prematurity","volume":"23","author":"Lee","year":"2021","journal-title":"Paediatr. Drugs"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/8755122515599552","article-title":"Ranibizumab: A Review of Its Use in the Treatment of Diabetic Retinopathy in Patients With Diabetic Macular Edema","volume":"32","author":"Akiyode","year":"2016","journal-title":"J. Pharm. Technol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1167\/iovs.61.13.22","article-title":"Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept","volume":"61","author":"Hong","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3345\/cep.2021.00773","article-title":"Retinopathy of prematurity: A review of epidemiology and current treatment strategies","volume":"65","author":"Hong","year":"2022","journal-title":"Clin. Exp. Pediatr."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ophtha.2012.01.003","article-title":"Current role of cryotherapy in retinopathy of prematurity: A report by the American Academy of Ophthalmology","volume":"119","author":"Simpson","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.survophthal.2016.12.004","article-title":"Advances in understanding and management of retinopathy of prematurity","volume":"62","author":"Hartnett","year":"2017","journal-title":"Surv. Ophthalmol."},{"key":"ref_67","first-page":"Cd009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.eye.6701729","article-title":"Argon laser photocoagulation for retinopathy of prematurity: Long-term outcome","volume":"19","author":"Ospina","year":"2005","journal-title":"Eye"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1515\/jpm-2015-0357","article-title":"Oral propranolol in early stages of retinopathy of prematurity","volume":"44","author":"Bancalari","year":"2016","journal-title":"J. Perinat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jpeds.2013.07.049","article-title":"Oral propranolol for retinopathy of prematurity: Risks, safety concerns, and perspectives","volume":"163","author":"Filippi","year":"2013","journal-title":"J. Pediatr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fped.2019.00180","article-title":"Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study","volume":"7","author":"Filippi","year":"2019","journal-title":"Front. Pediatr."},{"key":"ref_72","first-page":"Cd011893","article-title":"Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants","volume":"3","author":"Kaempfen","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/02713683.2016.1158272","article-title":"The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index","volume":"42","author":"Korkmaz","year":"2017","journal-title":"Curr. Eye Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/s41372-019-0503-x","article-title":"Oral propranolol in prevention of severe retinopathy of prematurity: A systematic review and meta-analysis","volume":"39","author":"Stritzke","year":"2019","journal-title":"J. Perinatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1002\/hep.27679","article-title":"Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats","volume":"61","author":"Hsu","year":"2015","journal-title":"Hepatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/jcp.22180","article-title":"Caffeine induces matrix metalloproteinase-2 (MMP-2) and MMP-9 down-regulation in human leukemia U937 cells via Ca2+\/ROS-mediated suppression of ERK\/c-fos pathway and activation of p38 MAPK\/c-jun pathway","volume":"224","author":"Liu","year":"2010","journal-title":"J. Cell Physiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3346\/jkms.2015.30.12.1828","article-title":"Early Caffeine Use in Very Low Birth Weight Infants and Neonatal Outcomes: A Systematic Review and Meta-Analysis","volume":"30","author":"Park","year":"2015","journal-title":"J. Korean Med. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa073679","article-title":"Long-term effects of caffeine therapy for apnea of prematurity","volume":"357","author":"Schmidt","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nm1591","article-title":"Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis","volume":"13","author":"Connor","year":"2007","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamapediatrics.2020.5653","article-title":"Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity: A Randomized Clinical Trial","volume":"175","author":"Nilsson","year":"2021","journal-title":"JAMA Pediatr."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1542\/peds.2012-0517","article-title":"Meta-analysis of LCPUFA supplementation of infant formula and visual acuity","volume":"131","author":"Qawasmi","year":"2013","journal-title":"Pediatrics"},{"key":"ref_82","first-page":"Cd000501","article-title":"Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants","volume":"4","author":"Darlow","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13052-020-00837-0","article-title":"Oral vitamin A supplementation for ROP prevention in VLBW preterm infants","volume":"46","author":"Garofoli","year":"2020","journal-title":"Ital. J. Pediatr."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"267","DOI":"10.33549\/physiolres.930754","article-title":"Inhibition of vascular endothelial growth factor-induced retinal neovascularization by retinoic acid in experimental retinopathy of prematurity","volume":"55","author":"Ozkan","year":"2006","journal-title":"Physiol. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1097\/IAE.0000000000002543","article-title":"Early vitamin a supplementation improves the outcome of retinopathy of prematurity in extremely preterm infants","volume":"40","author":"Sun","year":"2020","journal-title":"Retina"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S0022-3476(05)81247-8","article-title":"Tissue levels of polyunsaturated fatty acids during early human development","volume":"120","author":"Martinez","year":"1992","journal-title":"J. Pediatr."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11745-003-1065-1","article-title":"The potential role for arachidonic and docosahexaenoic acids in protection against some central nervous system injuries in preterm infants","volume":"38","author":"Crawford","year":"2003","journal-title":"Lipids"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00359-020-01403-z","article-title":"Vitamin A: Its many roles-from vision and synaptic plasticity to infant mortality","volume":"206","author":"Dowling","year":"2020","journal-title":"J. Comp. Physiol. A Neuroethol. Sens. Neural. Behav. Physiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MOP.0b013e3283423e51","article-title":"Future applications of antioxidants in premature infants","volume":"23","author":"Lee","year":"2011","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_90","first-page":"Cd003665","article-title":"Vitamin E supplementation for prevention of morbidity and mortality in preterm infants","volume":"4","author":"Brion","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_91","first-page":"Cd001073","article-title":"D-Penicillamine for preventing retinopathy of prematurity in preterm infants","volume":"2013","author":"Qureshi","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14767058.2020.1712700","article-title":"Lutein supplementation and retinopathy of prematurity: A meta-analysis","volume":"35","author":"Cota","year":"2022","journal-title":"J. Matern.-Fetal Neonatal Med."},{"key":"ref_93","first-page":"75","article-title":"Retinopathy of prematurity and antenatal corticosteroids. The Italian ROP Study Group","volume":"68","author":"Console","year":"1997","journal-title":"Acta Biomed. Atenei Parm."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archopht.116.5.601","article-title":"Antenatal dexamethasone and decreased severity of retinopathy of prematurity","volume":"116","author":"Higgins","year":"1998","journal-title":"Arch. Ophthalmol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s11596-019-2064-9","article-title":"Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis","volume":"39","author":"Zhong","year":"2019","journal-title":"Curr. Med. Sci."},{"key":"ref_96","first-page":"Cd001146","article-title":"Early (<8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants","volume":"10","author":"Doyle","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_97","first-page":"Cd001145","article-title":"Late (>7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants","volume":"10","author":"Doyle","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/s-2000-13437","article-title":"Do postnatal glucocorticoids and retinopathy of prematurity relate?","volume":"17","author":"Termote","year":"2000","journal-title":"Am. J. Perinatol"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJM199805283382202","article-title":"Lack of Efficacy of Light Reduction in Preventing Retinopathy of Prematurity","volume":"338","author":"Reynolds","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_100","first-page":"Cd000122","article-title":"Early light reduction for preventing retinopathy of prematurity in very low birth weight infants","volume":"2013","author":"Jorge","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Natoli, R., Valter, K., Barbosa, M., Dahlstrom, J., Rutar, M., Kent, A., and Provis, J. (2013). 670nm photobiomodulation as a novel protection against retinopathy of prematurity: Evidence from oxygen induced retinopathy models. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0072135"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41390-019-0520-7","article-title":"A pilot randomised clinical trial of 670\u2009nm red light for reducing retinopathy of prematurity","volume":"87","author":"Kent","year":"2020","journal-title":"Pediatric Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1167\/iovs.06-0057","article-title":"Comparative effects of early postnatal ibuprofen and indomethacin on VEGF, IGF-I, and GH during rat ocular development","volume":"47","author":"Beharry","year":"2006","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"272.e1","DOI":"10.1016\/j.jaapos.2021.04.011","article-title":"The effect of ibuprofen and caffeine prophylaxis on retinopathy of prematurity","volume":"25","author":"Schumacher","year":"2021","journal-title":"J. AAPOS"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1203\/00006450-199908000-00010","article-title":"Indomethacin improves oxygen-induced retinopathy in the mouse","volume":"46","author":"Nandgaonkar","year":"1999","journal-title":"Pediatr. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpeds.2008.01.031","article-title":"Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: A multicenter, randomized, controlled trial","volume":"153","author":"Jegatheesan","year":"2008","journal-title":"J. Pediatr."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Avila-Vazquez, M., Maffrand, R., Sosa, M., Franco, M., De Alvarez, B.V., Cafferata, M.L., and Bergel, E. (2004). Treatment of retinopathy of prematurity with topical ketorolac tromethamine: A preliminary study. BMC Pediatr., 4.","DOI":"10.1186\/1471-2431-4-15"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3928\/01913913-20100920-01","article-title":"Effectiveness of ketorolac tromethamine in prevention of severe retinopathy of prematurity","volume":"48","author":"Giannantonio","year":"2011","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial (2000). I: Primary outcomes. Pediatrics, 105, 295\u2013310.","DOI":"10.1542\/peds.105.2.295"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/jamapediatrics.2014.3307","article-title":"Oxygen saturation target range for extremely preterm infants: A systematic review and meta-analysis","volume":"169","author":"Manja","year":"2015","journal-title":"JAMA Pediatr."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1055\/s-0036-1586109","article-title":"Role of Insulinlike Growth Factor 1 in Fetal Development and in the Early Postnatal Life of Premature Infants","volume":"33","author":"Ley","year":"2016","journal-title":"Am. J. Perinatol."},{"key":"ref_112","first-page":"322","article-title":"Breast-feeding and growth factors in preterm newborn infants","volume":"24","author":"Domenech","year":"1997","journal-title":"J. Pediatr Gastroenterol. Nutr."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3889\/oamjms.2019.035","article-title":"Effect of Early Breast Milk Nutrition on Serum Insulin-Like Growth Factor-1 in Preterm Infants","volume":"7","author":"Alzaree","year":"2019","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/jp.2016.98","article-title":"Systematic review and meta-analysis of human milk intake and retinopathy of prematurity: A significant update","volume":"36","author":"Bharwani","year":"2016","journal-title":"J. Perinatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1203\/PDR.0b013e3181973dc8","article-title":"Oxygen-Induced Retinopathy in Mice: Amplification by Neonatal IGF-I Deficit and Attenuation by IGF-I Administration","volume":"65","author":"Vanhaesebrouck","year":"2009","journal-title":"Pediatric Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jpeds.2018.10.033","article-title":"rhIGF-1\/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial","volume":"206","author":"Ley","year":"2019","journal-title":"J. Pediatr."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"107675","DOI":"10.1016\/j.pharmthera.2020.107675","article-title":"The roles of non-coding RNAs in vascular calcification and opportunities as therapeutic targets","volume":"218","author":"Ryu","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00439-018-1931-y","article-title":"Non-coding RNAs in retinal development and function","volume":"138","author":"Karali","year":"2019","journal-title":"Hum. Genet."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41569-019-0218-x","article-title":"RNA-based diagnostic and therapeutic strategies for cardiovascular disease","volume":"16","author":"Lu","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.1038\/s41380-021-01303-x","article-title":"Obesity-linked circular RNA circTshz2-2 regulates the neuronal cell cycle and spatial memory in the brain","volume":"26","author":"Yoon","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics\u2014Challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Chen, N., Wang, J., Hu, Y., Cui, B., Li, W., Xu, G., Liu, L., and Liu, S. (2014). MicroRNA-410 Reduces the Expression of Vascular Endothelial Growth Factor and Inhibits Oxygen-Induced Retinal Neovascularization. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095665"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"12163","DOI":"10.1073\/pnas.1508426112","article-title":"Endothelial microRNA-150 is an intrinsic suppressor of pathologic ocular neovascularization","volume":"112","author":"Liu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"118299","DOI":"10.1016\/j.lfs.2020.118299","article-title":"Effect and mechanism of the long noncoding RNA MALAT1 on retinal neovascularization in retinopathy of prematurity","volume":"260","author":"Wang","year":"2020","journal-title":"Life Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"112783","DOI":"10.1016\/j.yexcr.2021.112783","article-title":"Competing endogenous RNA network associated with oxygen-induced retinopathy: Expression of the network and identification of the MALAT1\/miR-124-3p\/EGR1 regulatory axis","volume":"408","author":"Xia","year":"2021","journal-title":"Exp. Cell Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1167\/iovs.63.1.37","article-title":"The Long-Noncoding RNA TUG1 Regulates Oxygen-Induced Retinal Neovascularization in Mice via MiR-299","volume":"63","author":"Wang","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.7150\/thno.19353","article-title":"Silencing Of Circular RNA-ZNF609 Ameliorates Vascular Endothelial Dysfunction","volume":"7","author":"Liu","year":"2017","journal-title":"Theranostics"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/iub.2307","article-title":"CircPDE4B inhibits retinal pathological angiogenesis via promoting degradation of HIF-1\u03b1 though targeting miR-181c","volume":"72","author":"Deng","year":"2020","journal-title":"IUBMB Life"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"806","DOI":"10.18240\/ijo.2020.05.17","article-title":"Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: A Meta-analysis","volume":"13","author":"Wang","year":"2020","journal-title":"Int. J. Ophthalmol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1124\/jpet.119.256933","article-title":"Ocular Drug Delivery: Present Innovations and Future Challenges","volume":"370","author":"Gote","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"Pavlakis","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(16)31715-9","article-title":"Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: A phase 1B, double-blind, randomised controlled trial","volume":"389","author":"Stelma","year":"2017","journal-title":"Lancet"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Ochoa, S., and Milam, V.T. (2020). Modified Nucleic Acids: Expanding the Capabilities of Functional Oligonucleotides. Molecules, 25.","DOI":"10.3390\/molecules25204659"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Thi, T.T.H., Suys, E.J.A., Lee, J.S., Nguyen, D.H., Park, K.D., and Truong, N.P. (2021). Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9040359"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1167\/iovs.09-4951","article-title":"Outgrowth endothelial cells: Characterization and their potential for reversing ischemic retinopathy","volume":"51","author":"Medina","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.lfs.2012.07.019","article-title":"Circulating endothelial progenitor cells are reduced in rat oxygen-induced retinopathy despite a retinal SDF-1\/CXCR4 and VEGF proangiogenic response","volume":"91","author":"Villalvilla","year":"2012","journal-title":"Life Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1172\/JCI29683","article-title":"Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy","volume":"116","author":"Ritter","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/01.RES.0000099245.08637.CE","article-title":"Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells","volume":"93","author":"Fujiyama","year":"2003","journal-title":"Circ. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/labinvest.2011.141","article-title":"Bone marrow-derived monocyte lineage cells recruited by MIP-1\u03b2 promote physiological revascularization in mouse model of oxygen-induced retinopathy","volume":"92","author":"Ishikawa","year":"2012","journal-title":"Lab. Investig."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000492838","article-title":"Efficacy and Safety of Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Patients with Diabetic Retinopathy","volume":"49","author":"Gu","year":"2018","journal-title":"Cell Physiol. Biochem."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e131828","DOI":"10.1172\/jci.insight.131828","article-title":"iPSC-derived endothelial cell response to hypoxia via SDF1a\/CXCR4 axis facilitates incorporation to revascularize ischemic retina","volume":"5","author":"Cho","year":"2020","journal-title":"JCI Insight"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.4114","article-title":"Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration","volume":"36","author":"Fynes","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaophthalmol.2017.5453","article-title":"Vision Loss Secondary to Autologous Adipose Stem Cell Injections: A Rising Problem","volume":"136","author":"Rong","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13287-021-02134-x","article-title":"Transplantation of retinal pigment epithelium and photoreceptors generated concomitantly via small molecule-mediated differentiation rescues visual function in rodent models of retinal degeneration","volume":"12","author":"Surendran","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: Overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1006\/mthe.2002.0702","article-title":"Inhibition of Retinal Neovascularization by Intraocular Viral-Mediated Delivery of Anti-angiogenic Agents","volume":"6","author":"Auricchio","year":"2002","journal-title":"Mol. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.molcel.2015.04.028","article-title":"Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR","volume":"58","author":"Boettcher","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.omtn.2017.08.016","article-title":"In Vivo Knockout of the Vegfa Gene by Lentiviral Delivery of CRISPR\/Cas9 in Mouse Retinal Pigment Epithelium Cells","volume":"9","author":"Holmgaard","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.omtm.2020.01.006","article-title":"Factors Impacting Efficacy of AAV-Mediated CRISPR-Based Genome Editing for Treatment of Choroidal Neovascularization","volume":"17","author":"Chung","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1167\/iovs.17-21902","article-title":"AAV-CRISPR\/Cas9-Mediated Depletion of VEGFR2 Blocks Angiogenesis In Vitro","volume":"58","author":"Wu","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1167\/iovs.16-20537","article-title":"Editing VEGFR2 Blocks VEGF-Induced Activation of Akt and Tube Formation","volume":"58","author":"Huang","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/s41467-018-04175-y","article-title":"CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration","volume":"9","author":"Koo","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"14500","DOI":"10.1038\/ncomms14500","article-title":"In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR-Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nbt1117-998","article-title":"First AAV gene therapy poised for landmark approval","volume":"35","author":"Smalley","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.preteyeres.2018.08.003","article-title":"Gene therapy for visual loss: Opportunities and concerns","volume":"68","author":"Lee","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0140-6736(15)00345-1","article-title":"Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial","volume":"386","author":"Rakoczy","year":"2015","journal-title":"Lancet"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/15\/8529\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:38Z","timestamp":1760140838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/15\/8529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":161,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["ijms23158529"],"URL":"https:\/\/doi.org\/10.3390\/ijms23158529","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}